Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Natera (NTRA – Research Report). The company’s shares ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report), ...

德克萨斯州奥斯汀讯——Natera, Inc.（纳斯达克股票代码：NTRA）的联合创始人兼董事Sheena Jonathan最近进行了一系列股票交易，这在最近的SEC文件中披露。Natera是一家过去一年股价飙升超过158%，目前市值227亿美元的公司。根据 InvestingPro ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift toward multi-cancer detection.

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

Guardant Health is a leader in liquid biopsy ... and Guardant commands the second-largest market share after the market leader Natera. Reveal’s differentiating feature is that it is "tumor ...

Is Guardant Health (GH) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Guardant Health specializes in precision oncology, developing advanced blood tests for cancer detection and management. The core of its business lies in liquid biopsies for both advanced-stage and ...